In the context of breast cancer vaccination, three HER2/neu-derived epitopes (E75, GP2 and AE37) (Table 1) have been developed into the vaccines, to promote the immune targeting of breast-cancer specific HER2/neu peptide and accelerate cytotoxic activity against HER2/neu-expressing cancer cells. This evidence concerns the gene ERBB2 and cancer.